AJAndreas Jeromin

Andreas Jeromin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Jeromin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jackson Streeter

    Banyan Biomarkers, Alachua, Florida, United States of America

    2 shared publications
  • Kevin K. W. Wang

    Center for Neurotrauma, Multiomics & Biomarkers (CNMB), Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, USA

    2 shared publications
  • Andreas Kastrup

    Department of Neurology, Klinikum Bremen-Ost und Bremen-Mitte, Bremen, Germany

    1 shared publication
  • Anne Kästner

    Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany

    1 shared publication
  • Gregory M. Rose

    Departments of Anatomy & Physiology, Southern Illinois University School of Medicine, Carbondale, Illinois, United States of America

    1 shared publication
  • Hai-Xia Zhu

    Department of Neurology, The Third Xiangya Hospital, Changsha, Hunan, China

    1 shared publication

Latest Publications

  • Open Access

    Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure

    by Stefania Mondello, Johanna Palmio, Jackson Streeter, Ronald L Hayes, Jukka Peltola, Andreas Jeromin

    Clinical and experimental studies have demonstrated that seizures can cause molecular and cellular responses resulting in neuronal damage. At present, there are no valid tests for assessing organic damage to the brain associated with seizure. The aim of this study was to investigate cerebrospinal fluid (CSF) and plasma concentrations of Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a sensitive indicator of acute injury to brain neurons, in patients with tonic–clonic or partial secondarily generalized seizures due to various etiologies.


  • Open Access

    Age-Related Intraneuronal Elevation of αII-Spectrin Breakdown Product SBDP120 in Rodent Forebrain Accelerates in 3×Tg-AD Mice

    by Yan Cai, Hai-Xia Zhu, Jian-Ming Li, Xue-Gang Luo, Peter R. Patrylo, Gregory M. Rose, Jackson Streeter, Ron Hayes, Kevin K. W. Wang, Xiao-Xin Yan, et al.

    Spectrins line the intracellular surface of plasmalemma and play a critical role in supporting cytoskeletal stability and flexibility. Spectrins can be proteolytically degraded by calpains and caspases, yielding breakdown products (SBDPs) of various molecular sizes, with SBDP120 being largely derived from caspase-3 cleavage. SBDPs are putative biomarkers for traumatic brain injury. The levels of SBDPs also elevate in the brain during aging and perhaps in Alzheimer’s disease (AD), although the cellular basis for this change is currently unclear. Here we examined age-related SBDP120 alteration in forebrain neurons in rats and in the triple transgenic model of AD (3×Tg-AD) relative to non-transgenic controls. SBDP120 immunoreactivity (IR) was found in cortical neuronal somata in aged rats, and was prominent in the proximal dendrites of the olfactory bulb mitral cells. Western blot and densitometric analyses in wild-type mice revealed an age-related elevation of intraneuronal SBDP120 in the forebrain which was more robust in their 3×Tg-AD counterparts. The intraneuronal SBDP120 occurrence was not spatiotemporally correlated with transgenic amyloid precursor protein (APP) expression, β-amyloid plaque development, or phosphorylated tau expression over various forebrain regions or lamina. No microscopically detectable in situ activated caspase-3 was found in the nuclei of SBDP120-containing neurons. The present study demonstrates the age-dependent intraneuronal presence of an αII-spectrin cleavage fragment in mammalian forebrain which is exacerbated in a transgenic model of AD. This novel neuronal alteration indicates that impairments in membrane protein metabolism, possibly due to neuronal calcium mishandling and/or enhancement of calcium sensitive proteolysis, occur during aging and in transgenic AD mice.


  • Open Access

    Circulating Damage Marker Profiles Support a Neuroprotective Effect of Erythropoietin in Ischemic Stroke Patients

    by Hannelore Ehrenreich, Anne Kästner, Karin Weissenborn, Jackson Streeter, Swetlana Sperling, Kevin K. Wang, Hans Worthmann, Ronald L. Hayes, Nico von Ahsen, Andreas Kastrup, et al.

    The German Multicenter EPO Stroke Trial, which investigated safety and efficacy of erythropoietin (EPO) treatment in ischemic stroke, was formally declared a negative study. Exploratory subgroup analysis, however, revealed that patients not receiving thrombolysis most likely benefited from EPO during clinical recovery, a result demonstrated in the findings of the Göttingen EPO Stroke Study. The present work investigated whether the positive signal on clinical outcome in this patient subgroup was mirrored by respective poststroke biomarker profiles. All patients of the German Multicenter EPO Stroke Trial nonqualifying for thrombolysis were included if they (a) were treated per protocol and (b) had at least two of the five follow-up blood samples for circulating damage markers drawn (n = 163). The glial markers S100B and glial fibrillary acid protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in serum on d 1, 2, 3, 4 and 7 poststroke. All biomarkers increased poststroke. Overall, EPO-treated patients had significantly lower concentrations (area under the curve) over 7 d of observation, as reflected by the composite score of all three markers (Cronbach α = 0.811) and by UCH-L1. S100B and GFAP showed a similar tendency. To conclude, serum biomarker profiles, as an outcome measure of brain damage, corroborate an advantageous effect of EPO in ischemic stroke. In particular, reduction in the neuronal damage marker UCH-L1 may reflect neuroprotection by EPO.